Cholangiocarcinoma is a rare cancer of the bile ducts, the tubes that carry digestive fluid from the liver. It's often caught late because early symptoms are vague, and treatment has historically been limited to chemotherapy and surgery when the tumor can be removed. Recent years have brought targeted therapies for people whose tumors carry specific genetic changes.
What's actually going on in research
Trials are testing targeted drugs for FGFR2 fusions, IDH1 mutations, and other genetic drivers found in subsets of patients. Immunotherapy combinations are being studied after some patients responded to checkpoint inhibitors. Researchers are also testing chemotherapy combinations, radiation techniques, and treatments for advanced disease that has spread to the liver or beyond.
Targeted therapies
FDA-approved drugs now block FGFR2 fusions and IDH1 mutations found in some cholangiocarcinomas. Trials are testing newer versions of these drugs and looking for additional genetic targets.
Immunotherapy combinations
Checkpoint inhibitors alone help a small fraction of patients, but trials are pairing them with chemotherapy or other immune drugs. Tumors with mismatch repair defects respond better to immunotherapy.
Locoregional treatments
Studies are testing radiation beads, ablation, and other techniques to treat tumors directly in the liver. These approaches may control disease when surgery isn't possible.
What to know before you search
Eligibility often depends on tumor location, whether it can be surgically removed, genetic test results, prior treatments, and liver function.
What types of trials are currently open
- Targeted therapy trials — Testing drugs that block specific genetic changes in your tumor, often after molecular testing identifies mutations like FGFR2 fusions or IDH1.
- Immunotherapy trials — Testing checkpoint inhibitors alone or with chemotherapy to help the immune system recognize cancer cells.
- Chemotherapy trials — Testing new combinations of chemotherapy drugs or comparing them to current standard regimens.
- Locoregional treatment trials — Testing radiation beads, ablation, or other treatments delivered directly to tumors in the liver.
- Surgical trials — Testing whether surgery combined with chemotherapy or radiation improves outcomes for tumors that can be removed.
Recently added Cholangiocarcinoma trials
HCCANANO-HOPE1: IRE After Chemotherapy for Locally Advanced Unresectable Perihilar Cholangiocarcinoma
Irreversible electroporation is a non-thermal ablative technology that uses high-voltage electric pulses to create permanent nanopores in tumor cell membranes, leading to apoptosis or other forms of cell death. Because the mechanism is primarily non-thermal, IRE may better preserve extracellular matrix, bile ducts, vessels, and other critical structures than thermal ablation, which is relevant for tumors adjacent to major vascular or biliary anatomy. The main anticipated clinical value of IRE in these protocols is local disease control and potential survival benefit when used after induction therapy in patients with non-progressive disease. The procedure may be performed by open or percutaneous access according to tumor location, safety considerations, and institutional expertise. Perioperative management, imaging guidance, and post-procedure monitoring will follow institutional standards. Post-IRE gastrointestinal dysfunction may occur. Symptom-directed supportive care, including electroacupuncture where appropriate and approved by the investigator, may be used as supportive management. Such care is not intended to replace oncologic treatment and will be recorded as concomitant treatment when administered.
Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma
This is a prospective, single-arm, phase II clinical study. Patients with advanced cholangiocarcinoma harboring FGFR2 fusions or rearrangements who have either not previously received standard therapy or have experienced treatment failure following standard therapy will be screened for eligibility and enrolled in the study after providing written informed consent.
Find Cholangiocarcinoma trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.